AlloSure Plus
Use
AlloSure Plus is an AI‑derived, clinically validated algorithm intended to support healthcare provider assessment of kidney transplant rejection risk by integrating results from the laboratory‑developed AlloSure donor‑derived cell‑free DNA (dd‑cfDNA) test with traditional clinical parameters, including eGFR, creatinine changes, proteinuria, and history of prior rejection. It is not intended to diagnose or direct treatment, but to provide an integrated risk stratification to aid clinical decision‑making.
Special Instructions
Not provided.
Limitations
AlloSure Plus is not intended to make diagnostic or treatment decisions and should be interpreted in the context of full clinical assessment. Clinical performance has been validated only when AlloSure dd‑cfDNA results are available; standalone use without AlloSure is not supported.
Methodology
Other
Biomarkers
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided